Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Sep;31(9):1438–1439. doi: 10.1128/aac.31.9.1438

Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.

A B Schryvers 1, J Ogunariwo 1, S Chamberland 1, A J Godfrey 1, H R Rabin 1, L E Bryan 1
PMCID: PMC174959  PMID: 3118800

Abstract

Beta-lactam resistance in Pseudomonas aeruginosa detected only during ceftazidime therapy of cystic fibrosis patients was studied. Evaluation of resistant and susceptible isolates from one patient and resistant laboratory derivatives indicated that elevated beta-lactamase levels were the primary determinant of resistance. Susceptible isolates outgrew resistant isolates on antibiotic-free medium.

Full text

PDF
1438

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  2. Blumer J. L., Stern R. C., Klinger J. D., Yamashita T. S., Meyers C. M., Blum A., Reed M. D. Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas. Am J Med. 1985 Aug 9;79(2A):37–46. doi: 10.1016/0002-9343(85)90259-1. [DOI] [PubMed] [Google Scholar]
  3. Bryan L. E., Van Den Elzen H. M., Tseng J. T. Transferable drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1972 Jan;1(1):22–29. doi: 10.1128/aac.1.1.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gold R., Overmeyer A., Knie B., Fleming P. C., Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis. 1985 Mar-Apr;4(2):172–177. doi: 10.1097/00006454-198503000-00012. [DOI] [PubMed] [Google Scholar]
  5. Gribble M. J., Chow A. W., Naiman S. C., Smith J. A., Bowie W. R., Sacks S. L., Grossman L., Buskard N., Growe G. H., Plenderleith L. H. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother. 1983 Sep;24(3):388–393. doi: 10.1128/aac.24.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoogkamp-Korstanje J. A., van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. J Antimicrob Chemother. 1983 Aug;12(2):175–183. doi: 10.1093/jac/12.2.175. [DOI] [PubMed] [Google Scholar]
  7. Masuda G., Tomioka S., Hasegawa M. Detection of beta-lactamase production by gram-negative bacteria. J Antibiot (Tokyo) 1976 Jun;29(6):662–664. doi: 10.7164/antibiotics.29.662. [DOI] [PubMed] [Google Scholar]
  8. Sanders C. C., Sanders W. E., Jr Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis. 1983 Jul-Aug;5(4):639–648. doi: 10.1093/clinids/5.4.639. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES